ENCHROMA
15.7.2024 18:09:34 CEST | Business Wire | Press release
Opera di Religione della Diocesi di Ravenna, EnChroma, manufacturers of lenses for color blind users, Francesca Carlone, sustainable designer and founder of the project, Fondazione Paolina Brugnatelli and ITRIA announce today an initiative to enhance the experience of color blind visitors. Starting July 19, 2024, visitors with this vision condition will be able to borrow special glasses during their visit to live for the first time the experience of seeing light and bright color mosaics. The project, called ColoRaMi - color mosaics, will be introduced on July 19 at Basilica di Sant’Apollinare Nuovo as part of the Ravenna Mosaici FOR ALL program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714597763/en/
Basilica di San Vitale: Agnus Dei. Normal colour vision and colour blind view (Graphic: Business Wire)
In Italy, approximately 2.5 million people are color blind, a vision condition affecting a higher number of men (8%) vs. women (0.5%) and approximately 350 million people worldwide. Whereas people with normal color vision can see over one million shades of color, people with color vision deficit only see 10% of tones and shades. As a result, colors can appear dull or even indistinguishable. EnChroma lenses allow people with deuteranomaly and protanomaly to perceive a much wider range of colors.
Artistic and cultural heritage is enhanced also by improving its accessibility, safety, and inclusiveness. Thanks to ColoRaMi, Ravenna's Mosaics will be the world's first mosaics to be made accessible to color blind people. Starting Friday, July 19, EnChroma glasses will be distributed free of charge at the following locations: Basilica of Sant’Apollinare Nuovo, Mausoleum of Galla Placidia, Basilica of San Vitale, Neonian Baptistry, Archiepiscopal Museum, and Sant’Andrea Chapel, thus enabling visitors to see for the first time the mosaics in all their chromatic complexity.
The opening event on July 19, at 3:00 p.m. will host a “live reveal” event, in which a number of color blind participants will share the daily challenges of color blindness and the difference made by EnChroma lenses in their viewing experience of the multicolor nuances of the mosaics.
EVENT INFO:
When: Friday, July 19 at 3:00 p.m.
Where: Basilica of Sant’Apollinare Nuovo
What's a Live Reveal:
A "Live Reveal" is an opportunity for volunteers to test EnChroma glasses for the first time and share their experience. At the end of the day, the volunteers may keep their custom-made glasses.
About EnChroma glasses:
EnChroma glasses are the product of two NIH research grants and of clinical studies conducted at UC Berkeley and UC Davis, USA. In 2016, EnChroma glasses were awarded the Tibbetts Award by the U.S. Small Business Administration for their innovative technology-driven impact on individual experience. EnChroma glasses use special optical filters that help people with color vision deficiency (protanomaly and deuteranomaly) experience a wider range of colors, perceiving them as more accurate, brighter, and sharper. Please note: EnChroma glasses do not treat color blindness and work for 9 out of 10 color blind wearers.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714597763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
